Despite a sharp post-earnings sell-off, ManpowerGroup’s organic growth, expanding operating income and turnaround plan point to solid long-term potential. With buybacks poised to resume and margins expected to improve, the stock may offer a compelling recovery opportunity.  ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌

October 19, 2026   |   Read online ManpowerGroup Stock Sinks on Q3 Results, But Fundamentals Stay Solid Despite a sharp post-earnings sell-off, ManpowerGroup’s organic growth, expanding operating income and turnaround plan point to solid long-term potential. With buybacks poised to resume and margins expected to improve, the stock may offer a compelling recovery opportunity. Do NOT Buy SpaceX – Do This Instead (From Stansberry Research) Key Points ManpowerGroup's stock dropped sharply after a surprise CEO transition announcement coincided with turnaround-related cost increases and a GAAP-to-adjusted earnings gap. Despite the sell-off, Q3 showed underlying strength, with 6% organic growth, widening operating income, and adjusted earnings per share beating expectations at $1.01. Analysts hold a cautious Hold rating with no Sell calls, while institutions appear confident in a future recovery. Special Report: The Fed’s next move (and your money) (From Traders Agency)   ManpowerGroup (NYSE: MAN) triggered a 16% decline in its stock price when it released Q3 results, creating a solid entry point for long-term investors. The company is in the midst of turnaround efforts, revealed core strengths, and the “bad” news wasn’t exactly unexpected, merely poorly timed. Among the factors that impaired price action was the surprise revelation that a longtime insider and current Chief Strategy Officer would take over as CEO. The board has indicated the transition as a natural course of business, and Becky Frankiewicz is the logical choice to lead the next business phase. The news was poorly timed because it came alongside visible impacts of turnaround efforts, i.e., rising costs and a significant variance between GAAP and adjusted earnings. The critical detail is that the company is positioning itself for sustainable growth and wider margins, and will begin to see the positive impacts of cost-cutting, efficiency improvements, and higher-margin revenue streams next year. Trump goes "all-in" on Grand Canyon energy breakthrough (Ad) A drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of Saudi Arabia's largest oil field, with potential to last two million years. While the One Big Beautiful Bill Act eliminated federal credits for solar, wind, and EVs, this energy source was reclassified alongside oil and nuclear power and given eight years of tax credits. Google signed a 15-year contract, and Bill Gates committed $100 million. One company controls the entire supply chain behind this discovery. See the ticker behind this Grand Canyon energy breakthrough now ManpowerGroup Has a Capital Return Catalyst Waiting to Be Unleashed ManpowerGroup is a cash flow machine, capable of sustaining a solid dividend and aggressive share buybacks. Although buybacks are effectively paused during the company's financial turnaround, they will likely resume at the prior pace within the next year or so. Historically, the count has declined by 3.5% to 4.5% annually, providing significant leverage for share prices and earnings growth. The dividend offers a reason to buy. Cut in 2025 alongside the buyback, the payout yields 3.5% with shares near long-term lows and is on track for robust increases. The caveat is that dividend increases will be tied to margin improvements expected in the coming year, leaving the market in limbo as it waits for better news. ManpowerGroup Grows in Q3, Margins Widen ManpowerGroup didn’t have a bad Q3, just one with headwinds and uncertainty. Revenue rose to $4.8 billion, up 4.4% year over year (YOY), but fell short of consensus by a slim margin. Growth was supported by expansion across all segments, with 6% systemwide organic growth, currency-neutral. Currency is a factor in the margin details, but not the only headwind, as restructuring costs also play a role. The key is that spotty weaknesses are improving, are offset by strengths, and systemwide results show progress. While gross margin contracted by 20 basis points, SG&A improved, leaving operating income up by 23.7%, GAAP net income up by 89%, and adjusted earnings per share at $1.01, up 24% YOY and as expected despite the top-line miss. The bad news is that earnings per share (EPS) fell short of expectations, fueling investor anxiety. Q4 guidance is a headwind for price action, with the EPS forecast below consensus, but the same caveats apply: the company is investing in its future and positioning for better performance next year. The question isn’t so much about what the company is spending today as about the long-term impact on operations. Execs target $200 million in operational savings by 2028, bolstering the outlook for improved capital returns over the next two to three years. 100% overnight gains? (Ad) Rumors are circulating that Elon Musk is preparing to acquire three publicly traded companies. Dr. Mark Skousen, who met Musk in person and called the SpaceX listing months early, says he has identified all three targets in what he calls Elon's $2.1 Trillion Hit List. See the three companies before the rumors become headlines. Get the details on all three companies now Manpower’s Major Catalyst? Improved Hiring Trends Business improvements are good despite hiring trends being as tepid as they are. Labor market data doesn’t reflect a downturn, but employers aren’t hiring robustly, merely holding on to the employees they have while they wait out rising oil prices, inflation, and interest rates. The International Monetary Fund estimates a broad-based acceleration in employment in mid-to-late 2027, driven by non-tech, cyclical industries and the effects of this year’s balance sheet strengthening. Analyst trends reflect a cautious stance, with only nine analysts tracked and the consensus rating at Hold. However, no Sell ratings are logged. Institutions reflect a high degree of confidence, owning more than 98% of the shares and buying in late 2026. They underpin the stock price bottom seen in the charts and are likely to buy the dip in Q4, given the deep discount and potential for turnaround efforts to gain traction in upcoming quarters. This year’s catalysts include platform upgrades, technological advancements, and shifts toward higher-margin business. The company is integrating AI and agentic tools into its platform, while also focusing on more specialized talent. Experis connects employers with in-demand IT employees while Talent Solutions provides end-to-end, data-driven strategies across the employee cycle. What the market gets wrong today is thinking economic headwinds and staffing headwinds will last forever. In this scenario, the market is pricing the stock as if there is no recovery ahead, pushing it to 19x earnings, a 50% discount to cyclical highs. Read this article online › Further Reading Rocket Lab's Neutron Delay Leaves Wall Street Bullish But Raises the Stakes for 2027 The investigation Porter spent tens of thousands to document (From Porter & Company) Does the AI Selloff Put Alphabet's Breakout in Doubt? Do Not Buy Another AI Stock Before Seeing This (From Brownstone Research) Bank Earnings Are Mixed—These 2 ETFs Offer Very Different Paths to a Recovery 3 Stocks Delivering Bigger Dividends Despite Market Uncertainty MarketBeat Week in Review – 10/12 - 10/16     Stay Ahead of the Market The best investment opportunities don't wait. Get our research and stock ideas delivered straight to your smartphone—so you never miss a market-moving opportunity. Our text alerts ensure you see timely stock ideas and professional research reports instantly, whether you're in a meeting, commuting, or away from your desk. Get Text Alerts from American Market News (free)   Update your email preferences or unsubscribe here © 2026 The Markets Daily | MarketBeat Media, LLC 345 N Reid Place #620 Sioux Falls, SD 57103, United States

(Nasdaq: NRXP) Hits Our Watchlist With 6 Key Potential Catalysts (Oversold Leaning Technicals)

Regulatory paperwork rarely makes headlines.

Any content you receive is for information purposes only. Always conduct your own research. *Sponsored (Nasdaq: NRXP) Hits Our Watchlist With 6 Key Potential Catalysts (Oversold Leaning Technicals) *Click Here To Get Our Alerts Faster Via SMS* October 19th Greetings Readers, Regulatory paperwork rarely makes headlines. A labeling letter from the FDA is about as dry as agency mail gets. Yet for NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), a review letter disclosed in mid-October may be the clearest sign yet that a long regulatory climb is nearing the summit. The FDA asked for minor changes only. Its main request was simple: submit sample labeling with the proposed brand name ahead of the November 10th, 2026 GDUFA goal date for the company's preservative-free ket-a-mine. That date did not appear by accident. The FDA's generic review office found only minor quality items in April, following a favorable bioequivalence determination in March. In September, the agency reclassified a vial-related amendment from major to minor and moved the goal date up to November 10th. Why does a preservative matter? Existing ket-a-mine products contain ben-ze-thonium chloride, a preservative no longer permitted in new formulations under FDA policy. NRx's version leaves it out, and the company points to physician-documented supply shortages as a reason the product is important. NRx is not waiting idly. Management has ordered 5Mn units of launch inventory and appointed its first Chief Commercial Officer, with planned capacity of 1Mn units per month after launch. The balance sheet has changed shape, too. Cash stood at approx. $26.7Mn on June 30th, up from $7.8Mn at year-end 2025, according to the company's second-quarter results. The first-half net loss narrowed to $18.0Mn from $23.1Mn a year earlier. Six steps on the preservative-fr-ee ket-a-mine review path. Graphic built from company releases and SEC filings. Behind The Scenes: The August Earnings Call NRx's second-quarter call played less like a status update and more like a launch briefing. NRx CEO Dr. Jonathan Javitt opened by calling the quarter “a major inflection point” for the company. The sharpest exchange came during Q&A. BTIG analyst Tom Schrader asked how the generic ket-a-mine, branded KETAFREE, would launch alongside the depression programs. Javitt drew a clean line: separate products, separate product codes and separate commercial paths. The KETAFREE label, he said, will not include depression. NRx CFO Michael Abrams then addressed the cash question head on. He told listeners current resources should support operations for at least a year, following a public offering with gross proceeds of more than $22Mn. The Pivot: From Pharmacy Shelf To Defense Lab The quarter's most strategic move happened outside the pharmacy. NRx formed NRx Defense Systems, a Florida subsidiary built to pair low-dose D-cycloserine, a key ingredient in NRX-101, with transcranial magnetic stimulation (TMS). That strategy now has federal backing. DARPA a-warded the subsidiary a prime contract worth approx. $11.2Mn to run SPARC-TMS, a randomized Phase II/III study of up to 400 adults with treatment-resistant depression. Patients receive robot-guided TMS over a single day plus five days of NRX-101. The design builds on published real-world findings of 91% treatment response and 69% remission at three months using traditional TMS with D-cycloserine. Partners include Harvard Medical School's McLean Hospital, Arizona State University and Zeta Surgical. If earlier results hold, NRx says the study could potentially support a future FDA filing for NRX-101. About NRx Pharmaceuticals, Inc. NRx is a clinical-stage biopharmaceutical company built on an NMDA platform for depression, suicidality, PTSD, and chronic pain. Its pipeline runs on three product tracks: KETAFREE is the preservative-free ket-a-mine under review through the generic (ANDA) pathway for the existing anesthesia label. NRX-100 is preservative-free IV ket-a-mine with Fast Track designation; after a Type C meeting, the FDA requested no additional trials for a planned application in severe depression. NRX-101, an oral D-cycloserine and lurasidone combination, holds Breakthrough Therapy Designation for suicidal bipolar depression. Revenue today comes from HOPE Therapeutics, the clinic subsidiary. The latest 10-Q shows HOPE operating six Florida locations offering ket-a-mine infusion, TMS and Spravato, built partly through the Dura Medical acquisition and the purchase of KMD Wellness clinic assets in Boca Raton. Patient service revenue reached approx. $2.2Mn in the first half of 2026. More Sources: NRXP Website. 6 Potential Catalysts Carry (Nasdaq: NRXP) To Our Top Watchlist Spot #1. A Federal Goal Date Is Now Firmly On The Calendar. The FDA has set November 10th, 2026 as the GDUFA goal date for the preservative-fr-ee ket-a-mine application from NRx NRXP, following a request for only minor labeling changes. #2. Launch Inventory Is Already Ordered And Waiting. Management says NRXP has ordered 5Mn units of launch inventory ahead of a potential approval decision. #3. Non-Dilutive DARPA Funding Backs A Potential Registration Trial. The approx. $11.2Mn SPARC-TMS contract gives NRXP federal funding for a study the company says could potentially support a future NRX-101 filing. #4. An FDA Path For NRX-100 Without New Trials. FDA meeting minutes indicate NRXP can pursue its NRX-100 application using existing controlled trial data plus real-world evidence. #5. Analyst Coverage Points To Significant Targets. 2026 ratings on NRXP tracked by Benzinga are positive, with Ascendiant Capital raising its target to $50 on October 1st and a five-analyst consensus near $30. #6. Multiple Technical Indicators Flashing Oversold Signals. At close on Friday, Barchart was reporting multiple technical indicators to be flashing oversold signals for NRXP including a 9-Day and 14-Day Relative Strength Index both below 31%. The Bottom Line NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) has spent years building toward one regulatory moment, and that moment now has a date. Add a DARPA-funded trial, a Florida clinic network, and a stronger balance sheet, and NRXP carries more moving parts than a quick glance suggests. It also lists an expected earnings date of November 12th, just two days after the goal date. We’re initiating coverage on NRx Pharmaceuticals, Inc. (Nasdaq: NRXP). Be on the lookout for updates coming out soon. Talk again shortly. Sincerely, Kai Parker StockWireNews (Always Remember The St-ock Prices Could Be Significantly Lower Now From The Dates I Provided.) *StockWireNews.com (“StockWireNews” or “SWN” ) is owned by SWN Media LLC, a single member limited liability company. Data is provided from third-party sources and SWN is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile SWN brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in-vest-ment advice, are not in-vest-ment advisors, and any profiles we mention are not suitable for all in-vest-ors. Pursuant to an agreement between SWN Media LLC and TD Media LLC, SWN Media LLC has been hired for a period beginning on 10/18/2026 and ending on 10/19/2026 to publicly disseminate information about (NRXP:US) via digital communications. Under this agreement, TD Media LLC has paid SWN Media LLC seventeen thousand five hundred USD ("Funds"). These Funds were part of the forty thousand USD funds that TD Media LLC received from a third party named DMS Consulting LLC who did not receive the Funds directly or indirectly from the Issuer and does not own st-ock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices. Neither SWN Media LLC, TD Media LLC and their member own shares of (NRXP:US). Please see important disclosure information here: https://stockwirenews.com/disclosure/nrxp-teshw/#details

SWN Media | 4808 NW 2nd Ave Unit #388 | Boca Raton, FL 33431 US Unsubscribe | Constant Contact Data Notice